| Předmět: |
|
| Zdroj: |
Health & Medicine Week; 12/22/2023, p7609-7609, 1p |
| Abstrakt: |
A study conducted by researchers at Vrije Universiteit Amsterdam explored the perceived value of additional diagnostic testing with amyloid-PET in healthy participants acting as patients with mild cognitive impairment (MCI). The study involved 1,431 healthy participants who were asked to identify with a presented case of an MCI patient and indicate whether they would prefer additional testing with amyloid PET. The majority of participants (87%) preferred additional testing, and the median monetary value they were willing to pay for the testing was €1500. The willingness to pay increased if the testing resulted in better patient management and a delay in institutionalization. The study concluded that members of the general population acting as MCI patients are willing to pay a substantial amount for amyloid-PET, especially if it leads to better patient management and the prospect of living longer at home. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
